Page last updated: 2024-09-03
vadimezan and Glioma
vadimezan has been researched along with Glioma in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ching, LM; Connor, B; Guise, C; McGregor, A; Seyfoddin, V; Tijono, S; Yung, R | 1 |
| Ciesielski, MJ; Seshadri, M | 1 |
Other Studies
2 other study(ies) available for vadimezan and Glioma
| Article | Year |
|---|---|
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Female; Glioma; Infusions, Subcutaneous; Lenalidomide; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Random Allocation; Thalidomide; Xanthones | 2014 |
MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Cerebral Angiography; Contrast Media; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Treatment Outcome; Xanthones; Xenograft Model Antitumor Assays | 2009 |